Terms: = Prostate cancer AND TCF12, HEB, 6938, ENSG00000140262, HsT17266, HTF4
4 results:
1. High copy number variations, particular transcription factors, and low immunity contribute to the stemness of prostate cancer cells.
Dai Z; Liu P
J Transl Med; 2021 May; 19(1):206. PubMed ID: 33985534
[TBL] [Abstract] [Full Text] [Related]
2. Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive prostate cancer.
Vidal AC; Duong F; Howard LE; Wiggins E; Freedland SJ; Bhowmick NA; Gong J
Anticancer Res; 2020 Mar; 40(3):1459-1462. PubMed ID: 32132043
[TBL] [Abstract] [Full Text] [Related]
3. Decreased expression of tcf12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.
Chen QB; Liang YK; Zhang YQ; Jiang MY; Han ZD; Liang YX; Wan YP; Yin J; He HC; Zhong WD
Tumour Biol; 2017 Jun; 39(6):1010428317703924. PubMed ID: 28651494
[TBL] [Abstract] [Full Text] [Related]
4. Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis.
Thorsen K; Schepeler T; Øster B; Rasmussen MH; Vang S; Wang K; Hansen KQ; Lamy P; Pedersen JS; Eller A; Mansilla F; Laurila K; Wiuf C; Laurberg S; Dyrskjøt L; Ørntoft TF; Andersen CL
BMC Genomics; 2011 Oct; 12():505. PubMed ID: 21999571
[TBL] [Abstract] [Full Text] [Related]
